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Abstract
Objective: This study examined the time course of efficacy-related endpoints for lisdexamfet-
amine dimesylate (LDX) versus placebo in adults with protocol-defined moderate to severe binge-
eating disorder (BED).
Methods: In two 12-week, double-blind, placebo-controlled studies, adults meeting DSM-IV-TR
BED criteria were randomized 1:1 to receive placebo or dose-optimized LDX (50 or 70 mg).
Analyses across visits used mixed-effects models for repeated measures (binge eating days/week,
binge eating episodes/week, Yale-Brown Obsessive Compulsive Scale modified for Binge
Eating [Y-BOCS-BE] scores, percentage body weight change) and chi-square tests (Clinical Global
Impressions—Improvement [CGI-I; from the perspective of BED symptoms] scale dichotomized as
improved or not improved). These analyses were not part of the prespecified testing strategy, so
reported p values are nominal (unadjusted and descriptive only).
Results: Least squares mean treatment differences for change from baseline in both studies
favored LDX over placebo (all nominal p values < .001) starting at Week 1 for binge eating
days/week, binge-eating episodes/week, and percentage weight change and at the first post-
treatment assessment (Week 4) for Y-BOCS-BE total and domain scores. On the CGI-I, more
participants on LDX than placebo were categorized as improved starting at Week 1 in both
studies (both nominal p values < .001). Across these efficacy-related endpoints, the superiority
of LDX over placebo was maintained at each posttreatment assessment in both studies (all
nominal p values < .001).
Discussion: In adults with BED, LDX treatment appeared to be associated with improvement on
efficacy measures as early as 1 week, which was maintained throughout the 12-week studies.
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1 | INTRODUCTION
Lisdexamfetamine dimesylate (LDX) is approved for use in adults with
moderate to severe binge-eating disorder (BED) in the United States
(Vyvanse®, 2015). In two large, identically designed, 12-week,
dose-optimized, randomized, double-blind, placebo-controlled, Phase 3
studies in adults with protocol-defined moderate to severe BED,
dose-optimized LDX (50 or 70 mg/day) produced statistically superior
and clinically meaningful reductions in binge eating days/week at
weeks 11–12 (primary efficacy endpoint) versus placebo (McElroy
et al., 2015a). In these Phase 3 trials, statistically significant and clini-
cally meaningful improvements on secondary efficacy endpoints were
also observed for LDX versus placebo at Week 12/early termination
(ET) for including Clinical Global Impressions—Improvement (CGI-I) and
4-week binge eating cessation and at Week 12 for Yale-Brown
Obsessive Compulsive Scale modified for Binge Eating (Y-BOCS-BE)
and percentage change in body weight (McElroy et al., 2015a). In a
Phase 2, fixed-dose, randomized, double-blind, placebo-controlled trial,
LDX (50 and 70 mg but not 30 mg) was also superior to placebo in
decreasing binge eating days/week in adults with BED at Week 11
(McElroy et al., 2015b). In these short-term studies (McElroy et al.,
2015a,b), the safety and tolerability of LDX were generally similar to its
established profile for LDX treatment of attention-deficit/hyperactivity
disorder (ADHD) (Vyvanse®, 2015).
Although the main findings for the primary and key secondary effi-
cacy endpoints from the Phase 3 studies of LDX have been published
(McElroy et al., 2015a), these analyses only examined change from
baseline to end of study (Week 12 or Week 12/ET). Statistical assess-
ment of the time course of effects of LDX on efficacy-related end-
points from these studies has not yet been reported. Such data are
important because they provide an indication of how soon treatment
effects may be anticipated after the therapy is initiated. The current
report describes the time course of effects of LDX on efficacy-related
endpoints (binge eating days/week, binge eating episodes/week,
percentage of participants exhibiting improvement on the dichotom-
ized CGI-I, percentage of participants exhibiting 1-week binge eating
response, percentage change in body weight, and Y-BOCS-BE total
and subscale score changes) in the two previously described 12-week
treatment Phase 3 clinical studies (McElroy et al., 2015a).
2 | METHOD
2.1 | Study design and treatment
Detailed descriptions of study designs and participants have been
reported (McElroy et al., 2015a). In brief, two randomized, placebo-
controlled, parallel-group, multicenter studies (ClinicalTrials.gov identifier:
NCT01718483 [referred to hereafter as Study 1] and ClinicalTrials.gov
identifier: NCT01718509 [referred to hereafter as Study 2]) were
conducted. Study protocols were approved by ethics committees,
and both studies were conducted in accordance with International
Conference on Harmonisation Good Clinical Practice and the principles
of the Declaration of Helsinki. Participants provided written informed
consent before entering the studies.
Each study included a 2-week screening phase, a 12-week double-
blind phase (4 weeks of dose optimization followed by 8 weeks of dose
maintenance), and a follow-up visit. After screening, participants were
randomized 1:1 to receive 12 weeks of dose-optimized LDX or matching
placebo. For blinding, both treatments were identical in appearance. Treat-
ment was initiated with 30 mg LDX during Week 1 and titrated to 50 mg
LDX at the start of Week 2. DuringWeek 3, dose increases to 70 mg LDX
could be made based on tolerability and clinical need. After the LDX dose
was increased to 70mg, a single down-titration to 50mgwas allowed dur-
ing Week 3 if tolerability to 70 mg LDX was poor. If a dose reduction
occurred, no further changes were allowed. During Weeks 4 to 12, the
optimized LDX dosage (50 or 70 mg) was maintained. Because no dose
changes were permitted beyond Week 3, participants requiring a dose
reduction during the maintenance phase were discontinued. A follow-up
visit occurred 1 week after the final treatment visit (Week 12 or ET) to
assess any ongoing or new safety and tolerability issues.
2.2 | Participants
Participant inclusion and exclusion criteria have been reported previ-
ously (McElroy et al., 2015a). Eligible adults (aged 18–55 years) met the
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text
Revision (DSM-IV-TR) criteria for BED and had protocol-defined
moderate to severe BED (defined as having 3 binge eating days/week
for 14 days before baseline and Clinical Global Impressions—Severity
scores [from the perspective of binge eating symptoms] at screening
and baseline of 4). Key exclusion criteria included current anorexia
nervosa or bulimia nervosa; comorbid current psychiatric disorders
either controlled with prohibited medications or uncontrolled and asso-
ciated with significant symptoms or any condition that could confound
study assessments; lifetime history of psychosis, mania, hypomania,
dementia, or ADHD; a Montgomery–Åsberg Depression Rating Scale
total score 18 at screening; psychotherapy or weight loss support for
BED within 3 months of screening; being considered a suicide risk in the
opinion of the investigator, having a previous suicide attempt, or cur-
rently demonstrating active suicidal ideation; history of cardiovascular
disorders or moderate or severe hypertension; and lifetime history of
stimulant abuse, recent history of substance abuse or dependence, or
known or suspected intolerance or hypersensitivity to LDX or related
compounds.
2.3 | Endpoint measures
Binge eating days/week, binge eating episodes/week, and 1-week
binge eating response (percentage reductions in binge eating episodes/
week) data were based on participants’ daily self-reported binge eating
diaries as assessed and confirmed by experienced and trained clinicians.
Binge eating diaries were assessed at all study visits except screening.
The percentage of participants exhibiting 1-week binge eating
responses (reductions in binge-eating episodes/week of 100%,
99–75%, 74–50%, and <50%) was derived at each treatment visit.
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The CGI-I (Guy, 1976) measured changes in clinical severity
relative to baseline (score range: 1 [very much improved] to 7 [very
much worse]). The CGI-I was assessed from the perspective of BED
symptoms and administered at each postbaseline visit. CGI-I scores
were dichotomized as improved (very much improved and much
improved; scores of 1 or 2) or not improved (minimally improved to
very much worse; scores of 3–7).
The Y-BOCS-BE, a 10-item, clinician-rated scale (item scores: 0
[no symptoms] to 4 [extreme symptoms]), assessed the obsessiveness
of binge eating thoughts and compulsiveness of binge eating behaviors.
Total scores range from 0 to 40. The Y-BOCS-BE, which is a modified
version of the Yale-Brown Obsessive Compulsive Scale (Goodman
et al., 1989), has been validated in adults with BED (Deal et al., 2015).
The Y-BOCS-BE was administered at baseline and Weeks 4, 8, and 12.
Body weight was measured at each visit, and the percentage change
from baseline was calculated for each treatment week.
2.4 | Data presentation and statistical analyses
Statistically significant findings for the prespecified primary efficacy
endpoint (change from baseline in binge eating days/week at Weeks
11–12) and key secondary endpoints (improvement on the dichotom-
ized CGI-I at Week 12/ET, 4-week binge cessation at Week 12/ET,
percentage body weight change from baseline at Week 12, and Y-
BOCS-BE total score change from baseline at Week 12) have previ-
ously been reported (McElroy et al., 2015a). Time course assessments
of efficacy-related endpoints are described in this report.
Statistical assessments were conducted in the full analysis set (par-
ticipants taking 1 study drug dose and having 1 postbaseline primary
efficacy assessment). The time course analyses presented in the current
report are analyzed with the same procedures previously described for
the prespecified endpoints (McElroy et al., 2015a). Mixed-effects mod-
els for repeated measures analysis over all postbaseline visits, using an
unstructured covariance matrix with treatment, visit, and the treatment
3 visit interaction included as factors and baseline score as a covariate
and its interaction with visit also included in the model, were used to
determine least squares (LS) mean treatment differences (LDX—placebo)
in the change from baseline for binge eating days/week, binge-eating
episodes/week, percentage body weight change, and Y-BOCS-BE total
and domain scores; effects size (ES) size was determined based on the
estimated standard deviation from the unstructured covariance matrix.
Degrees of freedom were calculated using the Kenward-Roger approxi-
mation method. Treatment comparisons between LDX and placebo in
the percentage of participants categorized as improved on the dicho-
tomized CGI-I were analyzed using v2 tests; odds ratios (ORs) were
FIGURE 1 Changes in the frequency of binge eating over time, full analysis set. Mean6 SD binge eating days/week (A: Study 1; B: Study
2) and mean6 SD binge-eating episodes/week (C: Study 1; D: Study 2). Abbreviations: LDX5lisdexamfetamine; Pbo5placebo
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calculated as LDX/placebo. For 1-week binge eating response (percent-
age reductions in binge eating episodes/week), differences in the distri-
bution of responses between LDX and placebo were compared using a
covariate-adjusted Cochran–Mantel–Haenszel method, with baseline
binge eating episodes/week included as the covariate. Cramer’s V was
calculated using a 2 3 4 contingency table at each visit to assess the
association between the treatment group and binge eating response;
values range from 0 (no association) to 1 (complete association).
Consistent with International Conference on Harmonisation
statistical guidelines (European Medicines Agency, 1998), the control
of multiplicity in each study was prespecified in the statistical analysis
plan; these procedures have previously been described (McElroy et al.,
2015a). The current post hoc time course analyses were not adjusted
for multiple comparisons. As such, the p values reported for these post
hoc time course analyses are nominal (unadjusted for multiplicity and
descriptive). In the results, descriptions of the post hoc time course
analyses and of the prespecified analyses included in the hierarchical
testing strategy are presented separately to more clearly differentiate
these analyses.
3 | RESULTS
3.1 | Participant disposition and demographics
Participant disposition has previously been reported (McElroy et al.,
2015a). In brief, most randomized participants completed each study. A
total of 68 participants did not complete Study 1 and 96 participants
did not complete Study 2. Relatively few participants discontinued
because of adverse events or lack of efficacy. The full analysis set
included 374 participants in Study 1 and 350 participants in Study 2.
In Study 1 and Study 2, respectively, most participants in the full
analysis set were white (77.8% [291/374] and 74.0% [259/350]), were
women (86.9% [325/374] and 86.3% [302/350]), and met criteria for
obesity (BMI 30.0 but <35 kg/m2: 25.4% [95/374] and 27.7%
[97/350]; BMI 35.0 but <40 kg/m2: 24.1% [90/374] and 22.3%
[78/350]; BMI 40.0 kg/m2: 17.6% [66/374] and 19.7% [69/350]).
Mean6 SD age and BMI, respectively, were 38.0610.32 years
and 33.4366.245 kg/m2 in Study 1 and 38.0610.04 years and
33.6166.272 kg/m2 in Study 2.
3.2 | Efficacy analyses
3.2.1 | Binge eating days/week and binge-eating
episodes/week
The baseline mean6 SD numbers of binge eating days/week and
binge-eating episodes/week, respectively, were 4.6061.210 and
5.9662.551 with placebo and 4.7961.271 and 6.4262.962 with
LDX in Study 1 and 4.8261.422 and 6.6263.797 with placebo and
4.6661.273 and 6.4063.463 with LDX in Study 2. The mean6 SD
numbers of binge eating days/week (Figure 1A,B) and binge eating epi-
sodes/week (Figure 1C,D) decreased with placebo and LDX from
Week 1 through Weeks 11–12 in both studies. For binge eating days/
week, LS mean (95% CI) treatment differences favored LDX from
Week 1 through Weeks 9–10 (all nominal p values< .001; all ES .57)
and at Weeks 11–12 (both p values< .001; both ES .83) in both
studies (Supporting Information Table 1). For binge eating episodes/
week, LS mean (95% CI) treatment differences also favored LDX over
placebo from Week 1 through Weeks 11–12 (all nominal p val-
ues< .001; all ES .60; Supporting Information Table 1).
3.2.2 | Improvement on the CGI-I
The percentage of participants categorized as improved on the CGI-I
increased over the course of both studies with placebo and LDX
(Figure 2A,B). In both studies, the percentage of participants
categorized as improved was greater with LDX than placebo
from Week 1 through Week 12 (all v2 statistics12.48; degrees of
freedom51; all nominal p values< .001; all ORs2.32) and at
Week 12/ET (both v2 statistics49.81; degrees of freedom51; both
p values< .001; both ORs5.12).
3.2.3 | 1-Week binge eating response (percentage reductions in
binge-eating episodes/week) The 1-week binge eating response
distributions differed between LDX and placebo in both studies
from Week 1 through Week 12 (all v2 statistics16.66 based on
FIGURE 2 Improvement on the CGI-I over time, full analysis set.
Percentage (95% CI) of participants categorized as improveda on
the CGI-I (A: Study 1; B: Study 2). aParticipants were categorized
as improved on the CGI-I if a score of 1 (very much improved) or 2
(much improved) was reported. bNominal p< .001; cp< .001
(prespecified key secondary endpoint included in the hierarchical
testing strategy, data previously published [McElroy et al, 2015a]).
dOne participant in the placebo group in Study 2 did not have a
valid Week 12/early termination assessment. Abbreviations: CGI-
I5Binge Eating Clinical Global Impressions–Improvement;
ET5early termination; LDX5lisdexamfetamine; Pbo5placebo
MCELROY ET AL. | 887
Cochran–Mantel–Haenszel tests; degrees of freedom51; all nominal
p values< .001; all Cramer’s Vs .28) and at Week 12/ET (both v2
statistics43.82 based on Cochran–Mantel–Haenszel tests; degrees of
freedom51; both nominal p values< .001; both Cramer’s Vs .40). The
percentages of participants exhibiting binge eating episode reductions of
100% and 99% to 75% in the last 7 days were numerically greater with
LDX than placebo fromWeek 1 toWeek 12 in both studies (Figure 3A,B).
3.2.4 | Body weight
Mean6 SD body weight decreased with LDX but not placebo over the
course of both studies (Figure 4A,B), resulting in larger mean6 SD
percentage decreases in body weight from baseline with LDX than pla-
cebo (Figure 4C,D). In both studies, the LS mean (95% CI) treatment
differences for the percentage body weight change from baseline
favored LDX over placebo from Week 1 through Week 10 (all nominal
p values< .001; all ES .56) and at Week 12 (both p values< .001;
both ES1.22) (Supporting Information Table 2).
3.2.5 | Y-BOCS-BE total and domain scores
Mean6 SD Y-BOCS-BE total scores (Figure 5A,B) and domain scores
(Figure 5C–F) decreased (i.e., improved) from baseline with placebo and
LDX during both studies at each of the three postbaseline assessment
time points. For Y-BOCS-BE total score changes from baseline (Support-
ing Information Table 2), LS mean (95% CI) treatment differences
favored LDX at Week 4 and Week 8 (all nominal p values< .001; all
ES .87) and at Week 12 (both p values< .001; both ES1.03) in both
studies. For the binge-related obsessions and binge-related compulsions
domain scores, LS mean (95% CI) treatment differences also favored
LDX over placebo at Weeks 4, 8, and 12 (all nominal p values< .001; all
ES .78; Supporting Information Table 2) in both studies.
FIGURE 3 1-week binge eating responses (reductions in binge-eating episodes/week) over time, full analysis set. Percentages of
participants exhibiting reductions in binge eating episodes/week over the prior 7 days (A: Study 1; B: Study 2). aNominal p< .001 for
distribution of binge eating responses. Abbreviations: ET5 early termination; LDX5 lisdexamfetamine
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4 | DISCUSSION
The key findings of this report are that the treatment effects of LDX
versus placebo were observed as early as the first week of treatment
across multiple endpoints (binge eating days/week, binge eating epi-
sodes/week, 1-week binge eating response, dichotomized improve-
ment on the CGI-I, and percentage change in body weight from
baseline) and at Week 4 on Y-BOCS-BE total and domain scores (the
first time point assessed). Furthermore, improvements were maintained
for the duration of the 12-week studies. These results support the rela-
tively rapid efficacy of LDX in reducing both binge eating behavior and
binge eating-related psychopathology in two studies (McElroy et al.,
2015a) in which 12 weeks of dose-optimized LDX was shown to pro-
duce significantly greater improvement than placebo at the end of the
study on several of these same measures. Consistent with the results
of the Phase 2 study (McElroy et al., 2015b), this post hoc analysis
revealed a possible treatment effect at Week 1, when 30 mg LDX was
being taken by study participants. This finding is difficult to explain
because 30 mg LDX was not statistically superior to placebo in reduc-
ing log-transformed binge eating days/week at the Week 11 (the pri-
mary endpoint) in the Phase 2 study (McElroy et al., 2015b). Although
30 mg LDX is a recommended starting titration dose for the treatment
of BED (Vyvanse®, 2015), it was not studied as a target treatment
dose based largely on the Phase 3 pivotal studies in which 30 mg LDX
was used only as an initial titration dose and not studied as a target
dose (McElroy et al., 2015a). Additional research with a study design
focused on this research question would be needed to draw firmer
conclusions.
Although medications other than LDX have been investigated
for potential use as BED pharmacotherapy in double-blind, placebo-
controlled trials, LDX is the only medication currently approved in
the United States for the treatment of adults with moderate to
severe BED (Vyvanse®, 2015). To our knowledge, this is the first
publication describing time course analyses of treatment effects by
week for the efficacy of a pharmacotherapy in individuals with BED.
Based on available data from short-term studies for other potential
BED therapies, numerically greater reductions in binge eating
frequency and body weight for active treatment versus placebo are
generally observed within 1–4 weeks of starting treatment
(Appolinario et al., 2003; Guerdjikova et al., 2012; Hudson et al.,
1998; McElroy et al., 2000, 2003, 2007; Wilfley et al., 2008). In one
study that reported statistical analysis of treatment effects prior to
the end of the study, significantly greater reductions in binge eating
days/week and weight for sibutramine versus placebo were
FIGURE 4 Reductions in body weight over time, full analysis set. Mean6 SD body weight in kg (A: Study 1; B: Study 2) and mean6 SD
percentage changes in body weight from baseline (C: Study 1; D: Study 2). Abbreviations: ET5 early termination; LDX5 lisdexamfetamine;
Pbo5placebo
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reported at treatment Weeks 2 and 4, respectively (Appolinario
et al., 2003).
The study has several limitations. These time course analyses were
not prespecified, were not included in the hierarchical testing strategy,
and did not account for multiple comparisons. Therefore, all findings
related to the time course of effects of LDX are nominal (unadjusted
for multiplicity and descriptive in nature). In addition, study participants
were mainly women, mainly white, and predominantly met criteria for
obesity. Study participants with current comorbid psychiatric disorders
that were controlled with prohibited medications or uncontrolled and
associated with significant symptoms were also excluded, as were
those with histories of psychosis, mania/hypomania, and ADHD (those
with mild mood or anxiety symptoms that did not meet diagnostic cri-
teria or require treatment could be included), which may limit the gen-
eralizability of the current findings to a more heterogeneous clinical
population. Lastly, it has been reported that in a majority of individuals
with bulimia nervosa (combined data from two studies; n5785) even-
tual nonresponse to fluoxetine at the end of 7–8 weeks of fluoxetine
treatment is unlikely if reductions in binge eating or vomiting of at least
60% are not observed after 3 weeks of fluoxetine treatment (Sysko,
FIGURE 5 Y-BOCS-BE total and domain scores over time, full analysis set. Mean6 SD Y-BOCS-BE total scores (A: Study 1; B: Study 2),
mean6 SD Y-BOCS-BE binge-related obsessions domain scores (C: Study 1; D: Study 2), and mean6 SD binge-related compulsions domain
scores (E: Study 1; F: Study 2). Abbreviations: LDX5lisdexamfetamine; Pbo5placebo; Y-BOCS-BE5Yale-Brown Obsessive Compulsive Scale
modified for Binge Eating
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Sha, Wang, Duan, & Walsh, 2010). It would also be of interest to assess
the relationship between early treatment response to LDX and long-
term outcomes in individuals with BED. However, these analyses were
not conducted so the degree to which short-term response to LDX
predicts long-term outcomes cannot be determined.
In conclusion, LDX appeared to be associated with improvement
in efficacy-related endpoints in adults with protocol-defined moderate
to severe BED after 1 week of treatment (after Week 4 [the first
assessment] for the Y-BOCS-BE) and these improvements were main-
tained for the course of the 12-week treatment period. These results
suggest that LDX reduces both binge eating behavior and binge eating-
related psychopathology soon after treatment is initiated.
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